Evidence map›Paper›PMID 42045928›Full record

ArticleBiology direct2026

SH3BGRL3 promotes radioresistance and immune evasion in triple-negative breast cancer by regulating Rab27a.

Li Wang, Fei Lu, Jingyan Gao, Yanli Li, Songqin Li, Man Li, Renyi Dong

Abstract read
In one paragraph

Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li Wang *Department of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519 Kunzhou Road, Xishan District, Kunming, 650000, China. wangli@kmmu.edu.cn.
Fei Lu *Department of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519 Kunzhou Road, Xishan District, Kunming, 650000, China.
Jingyan Gao *Department of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519 Kunzhou Road, Xishan District, Kunming, 650000, China.
Yanli LiDepartment of Oncology, The Second People's Hospital of Baoshan City, Baoshan, 678000, China.
Songqin LiDepartment of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519 Kunzhou Road, Xishan District, Kunming, 650000, China.
Man LiDepartment of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519 Kunzhou Road, Xishan District, Kunming, 650000, China.
Renyi DongDepartment of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519 Kunzhou Road, Xishan District, Kunming, 650000, China.

Funding

National Natural Science Foundation of China 82460576Xingdian Talents Support Program for young Talents XDYC-QNRC-2023-0189Yunnan Provincial Health Commission Medical Reserve Talent Training Program H2024022
6 · The paper itself

Abstract

objectiveThis study aims to elucidate the molecular mechanisms by which SH3BGRL3 regulates radiosensitivity and immune evasion in triple-negative breast cancer (TNBC).

methodsAn orthotopic TNBC model was established by injecting 4T1 cells into the mice. In vitro, BT549 cells were co-cultured with CD8+ T cells isolated to mimic the immune microenvironment. Cell proliferation was assessed by CCK-8 and colony formation assays, while migration was evaluated using Transwell. Key protein expression was analyzed by Western blot, immunofluorescence, and immunohistochemistry.

resultsOur study revealed that SH3BGRL3 is upregulated in TNBC, where its knockdown suppresses the proliferation and migration of irradiated BT549 cells in vitro and inhibits tumor growth in vivo. Additionally, SH3BGRL3 depletion downregulated ferroptosis-related proteins GPX4 and SLC7A11, elevated Fe²⁺, MDA, and lipid ROS levels, and reduced GSH-effects that were rescued by the ferroptosis inhibitor Fer-1. Our study further demonstrates that SH3BGRL3 knockdown reduces the expression of exhaustion markers (PD-1, TIM-3, LAG-3, TIGIT) on CD8⁺ T cells while increasing the secretion of effector molecules (IFNg, granzyme B, perforin). Notably, we found that Rab27a expression is also upregulated in TNBC, and SH3BGRL3 can bind to Rab27a and stabilize its protein level. Mechanistic studies revealed that knocking down SH3BGRL3 attenuates its interaction with Rab27a and reduces Rab27a expression, thereby promoting ferroptosis and enhancing radiosensitivity, while also inhibiting the Rab27a-mediated exosome release pathway, which in turn enhances CD8⁺ T cell function and suppresses tumor immune escape.

conclusionThis study demonstrates that SH3BGRL3 promotes radioresistance and immune evasion in triple-negative breast cancer by regulating Rab27a.

Indexed as

Immune Evasionrab27 GTP-Binding ProteinsRadiation ToleranceTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB Crab27 GTP-Binding ProteinsImmune evasionRab27aRadioresistanceSH3BGRL3Triple-negative breast cancer

Identifiers

PMID42045928
PMCPMC13251207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.